Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cue Biopharma (CUE) Return on Capital Employed (2018 - 2025)

Historic Return on Capital Employed for Cue Biopharma (CUE) over the last 8 years, with Q3 2025 value amounting to 1.85%.

  • Cue Biopharma's Return on Capital Employed fell 1400.0% to 1.85% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.85%, marking a year-over-year decrease of 1400.0%. This contributed to the annual value of 1.25% for FY2024, which is 3700.0% down from last year.
  • As of Q3 2025, Cue Biopharma's Return on Capital Employed stood at 1.85%, which was down 1400.0% from 3.22% recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Return on Capital Employed registered a high of 0.58% during Q1 2021, and its lowest value of 3.51% during Q1 2025.
  • For the 5-year period, Cue Biopharma's Return on Capital Employed averaged around 1.24%, with its median value being 0.86% (2023).
  • As far as peak fluctuations go, Cue Biopharma's Return on Capital Employed skyrocketed by 1300bps in 2021, and later tumbled by -22100bps in 2025.
  • Over the past 5 years, Cue Biopharma's Return on Capital Employed (Quarter) stood at 0.64% in 2021, then decreased by -15bps to 0.74% in 2022, then crashed by -47bps to 1.08% in 2023, then plummeted by -54bps to 1.67% in 2024, then dropped by -10bps to 1.85% in 2025.
  • Its Return on Capital Employed was 1.85% in Q3 2025, compared to 3.22% in Q2 2025 and 3.51% in Q1 2025.